knowledge -WSS

knowledge

author：knowledge 2025-10-01 23:39:27 - browse：8545

Neumora, a privately held biotech company, is moving into the final phase of testing with a novel treatment for depression that showed promise in a mid-stage trial.

The drug, a daily pill called navacaprant, led to statistically significant improvements over placebo on a measurement of disease severity for patients with moderate to severe major depressive disorder, Neumora said Tuesday. In the eight-week study, the medicine also led to improvements in patient-reported anhedonia, a reduced ability to experience pleasure that often accompanies severe depression.

Navacaprant’s statistically significant benefits came from a pre-specified subset of 100 patients in a study that enrolled 171 people. In the total population, including 71 patients who had mild to moderate disease, navacaprant’s effect on depressive symptoms was numerically superior to placebo but did not reach the threshold of statistical significance, missing the study’s primary endpoint.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： After John Oliver segment, STAT readers share their opioid

focus

WSS

Large hospital system sues Multiplan for low

O'Shea Sibley was killed after expressing queer joy by voguing, activists say

O'Shea Sibley was killed after expressing queer joy by voguing, activists say

Francis Collins on trust in science and how Covid communications failed

The tragedy of Johnson & Johnson’s Covid vaccine

'Disease catastrophe' looms in Sudan as health conditions deteriorate, medics warn

hotspot

knowledge

hotspot

Moonlake's readout produced a cash windfall. Risks remain

Copay coupons to count toward deductibles, after Biden court move

Supreme Court strikes down use of affirmative action

Faced with fears of OxyContin misuse, sales reps touted its safety

Activists slam private health insurers over coverage restrictions

Newly revealed memo details efforts to keep Trump in power following election loss

In Memoriam: Notable people who died in 2023

Humana cuts profit projections as Medicare Advantage costs soar

Dobbs anniversary: the lost opportunity of abortion as health care

NIH director takes cautious approach to Biden drug pricing priority

knowledge

New brain studies show LSD's effects on the brain in full color

Think you might have Covid

Novo acquires Inversago for up to $1 billion

Faced with fears of OxyContin misuse, sales reps touted its safety

Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs

GOP presidential candidates start declaring their loyalty

focus

entertainment

focus

leisure time